Please ensure Javascript is enabled for purposes of website accessibility

CDC Says Coronavirus Spread to Continue Into 2021

By Cory Renauer - Updated Mar 9, 2020 at 6:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The COVID-19 train has left the station, but we can still slow it down.

The number of Americans with confirmed COVID-19 infections skyrocketed over the weekend, as commercial diagnostic service providers helped the Centers for Disease Control (CDC) to unwind a tremendous testing backlog.

As the number of reported infections surpassed 600 on Monday, the director of the National Center for Immunization and Respiratory Diseases, Nancy Messonnier, held a press briefing to warn Americans to prepare for a long battle against the spreading coronavirus.

A gloved hand holds a vial marked COVID 19.

Image source: Getty Images.

People, get ready

Messonnier said the ongoing COVID-19 outbreak could continue spreading into 2021 while advising Americans at risk and their families to take precautions. The virus responsible for COVID-19 infections, SARS-CoV-2, can live on surfaces for days, and since none of our immune systems has seen this virus before, everyone is highly susceptible.

The number of new cases in the U.S. has more than tripled in a couple of days and will continue soaring now that Quest Diagnostics (DGX 2.78%) and its diagnostic service providing peers have received a green light to provide new testing services.

A study conducted by Cedars-Sinai suggests there could have been at least 9,000 people in the U.S. with COVID-19 infections at the beginning of March. Despite the getting off to a bad start, the rate at which COVID-19 spreads throughout the U.S. can still be mitigated by careful hand washing and social distancing. 

Help on the way

There are plenty of experimental vaccines in development that could help prevent infections from occurring, but drugmakers still need to test those vaccines over long stretches of time before we can be certain they're safe and effective.

Gilead Sciences (GILD 0.89%) is testing an antiviral infusion for severely affected patients called remdesivir, and anecdotal evidence suggests it works. Before remdesivir becomes widely available, though, we need to wait for more data from a larger group of treated patients.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$136.68 (2.78%) $3.70
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.36 (0.89%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.